Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mar Drugs
2017 Sep 13;159:. doi: 10.3390/md15090287.
Show Gene links
Show Anatomy links
APETx4, a Novel Sea Anemone Toxin and a Modulator of the Cancer-Relevant Potassium Channel KV10.1.
Moreels L
,
Peigneur S
,
Galan DT
,
De Pauw E
,
Béress L
,
Waelkens E
,
Pardo LA
,
Quinton L
,
Tytgat J
.
???displayArticle.abstract???
The human ether-à-go-go channel (hEag1 or KV10.1) is a cancer-relevant voltage-gated potassium channel that is overexpressed in a majority of human tumors. Peptides that are able to selectively inhibit this channel can be lead compounds in the search for new anticancer drugs. Here, we report the activity-guided purification and electrophysiological characterization of a novel KV10.1 inhibitor from the sea anemone Anthopleura elegantissima. Purified sea anemone fractions were screened for inhibitory activity on KV10.1 by measuring whole-cell currents as expressed in Xenopus laevis oocytes using the two-microelectrode voltage clamp technique. Fractions that showed activity on Kv10.1 were further purified by RP-HPLC. The amino acid sequence of the peptide was determined by a combination of MALDI- LIFT-TOF/TOF MS/MS and CID-ESI-FT-ICR MS/MS and showed a high similarity with APETx1 and APETx3 and was therefore named APETx4. Subsequently, the peptide was electrophysiologically characterized on KV10.1. The selectivity of the toxin was investigated on an array of voltage-gated ion channels, including the cardiac human ether-à-go-go-related gene potassium channel (hERG or Kv11.1). The toxin inhibits KV10.1 with an IC50 value of 1.1 μM. In the presence of a similar toxin concentration, a shift of the activation curve towards more positive potentials was observed. Similar to the effect of the gating modifier toxin APETx1 on hERG, the inhibition of Kv10.1 by the isolated toxin is reduced at more positive voltages and the peptide seems to keep the channel in a closed state. Although the peptide also induces inhibitory effects on other KV and NaV channels, it exhibits no significant effect on hERG. Moreover, APETx4 induces a concentration-dependent cytotoxic and proapoptotic effect in various cancerous and noncancerous cell lines. This newly identified KV10.1 inhibitor can be used as a tool to further characterize the oncogenic channel KV10.1 or as a scaffold for the design and synthesis of more potent and safer anticancer drugs.
Figure 1. MS/MS spectra characterizing the APETx4 sequence. (A) MALDI-PSD-TOF/TOF of the [M+H]+ species @m/z 4651.02 and (B) ESI-FT-ICR MS/MS (CID) of the [M+4H]4+ species @m/z 1163.76. The combination of the two spectra led to the characterization of the whole sequence (34 peptide bonds broken over 38). The isobaric amino acids L and I have been attributed by sequence homology with APETx1 and APETx3.
Figure 2. In the upper panel, a multiple sequence alignment of APETx4 and its homologous sea anemone peptides is shown. Peptide names recommended by UniProt and alternative names are given. A Clustal Omega sequence alignment was performed using CLC Main Workbench. Amino acid residues are colored according to the RasMol amino color scheme. Percentages of identity (% ID) were obtained using standard protein BLAST. In the lower panel, the amino acid sequence of APETx4 was modeled on an averaged structured obtained from the solution NMR structure of APETx1 (PDB ID: 1WQK) using Modeller and Chimera. The amino acid residues are colored according to the RasMol amino color scheme. The 5 amino acid residues that differ between APETx1 and APETx4 are displayed as sticks. The C- and N-terminal residues and the cysteine residues (4, 6, 20, 30, 37 and 38) are indicated.
Figure 3. Concentration- and state-dependent effect of APETx4 on evoked KV10.1 currents. (A) Representative KV10.1 current evoked by a 2 s pulse to 0 mV from the holding potential in control and toxin condition are shown in light gray. An exponential one phase association equation was used to fit the evoked currents (black lines); (B) Concentration-dependency plot fitted with a logistic equation shows the current inhibition (%) in function of APETx4 concentration; (C) The normalized current (I/Imax) was plotted versus the APETx4 incubation time. The time points were fitted with a one-phase decay exponential equation; (D) The state-dependency plot shows the normalized current in control conditions and in toxin condition. During the APETx4 addition the cell membrane potential was clamped at â90 mV for 10 min. All measurements were performed in external ND96 solution.
Figure 4. Voltage-dependent effect of APETx4 on evoked KV10.1 currents. (A) Normalized currents elicited in ND96 solution (2 mM Ko) were plotted versus the applied pulse potentials (mV) in control (â) and toxin condition (â). The data points were fitted with the Boltzmann equation; (B) Normalized currents elicited in HK solution (96 mM Ko) were plotted versus the applied pulse potentials (mV) in control (â) and toxin condition (â). The data points were fitted with the Boltzmann equation; (C) The inhibited current (%) observed after 1.6 µM APETx4 addition in ND96 (â) and HK (â) solution was plotted versus the applied pulse potentials; (D) Effect of APETx4 on the inactivation properties of KV10.1. The non-inactivating channel fraction (I2/I2,max) was plotted against the corresponding prepulse potential (mV) in control (â) and toxin condition (â).
Figure 5. Selectivity screening on a panel of NaV and KV channels. The current inhibition (%) observed after addition of 1.6 µM APETx4 to various channels is displayed in a bar graph. Values are shown as average ± SEM of at least 3 independent experiments.
Figure 6. Voltage-dependent effect of APETx4 on hERG inward tail currents. (A) Normalized inward tail currents were plotted versus the applied pulse potentials (mV) in control (â) and toxin condition (â). The data points were fitted with the Boltzmann equation. (B) The inhibited current (%) observed after 10 µM APETx4 addition was plotted versus the applied pulse potentials.
Figure 7. Investigation of the proapoptotic effect of APETx4 on various cell lines using a Caspase-3/7 Reagent. The amount of cells in early apoptosis was plotted as Green Object Count (1/mm²) versus time (hours). The data points represented as red triangles were obtained from apoptosis experiments with cells incubated without APETx4, the green squares represent experiments with 20 µM APETx4 and the blue circles were obtained from experiments with 50 µM APETx4.
Figure 8. A multiple sequence alignment of various gating modifier toxins was performed using Clustal Omega (EMBL-EBI). Cysteine residues are highlighted in grey and the hydrophobic residues; Y4, L5, F6 that are functionally important for the activity of SGTx on the KV2.1 channel.
Agarwal,
The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia.
2010, Pubmed
Agarwal,
The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia.
2010,
Pubmed
Asher,
The Eag potassium channel as a new prognostic marker in ovarian cancer.
2010,
Pubmed
Asher,
Eag and HERG potassium channels as novel therapeutic targets in cancer.
2010,
Pubmed
Asher,
The role of Eag and HERG channels in cell proliferation and apoptotic cell death in SK-OV-3 ovarian cancer cell line.
2011,
Pubmed
Bruhn,
Isolation and characterisation of five neurotoxic and cardiotoxic polypeptides from the sea anemone Anthopleura elegantissima.
2001,
Pubmed
Catterall,
Voltage-gated ion channels and gating modifier toxins.
2007,
Pubmed
Ding,
Aberrant expression of ether à go-go potassium channel in colorectal cancer patients and cell lines.
2007,
Pubmed
Ding,
Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines.
2007,
Pubmed
Ding,
Expression and prognostic roles of Eag1 in resected esophageal squamous cell carcinomas.
2008,
Pubmed
Diochot,
APETx1, a new toxin from the sea anemone Anthopleura elegantissima, blocks voltage-gated human ether-a-go-go-related gene potassium channels.
2003,
Pubmed
Diochot,
A new sea anemone peptide, APETx2, inhibits ASIC3, a major acid-sensitive channel in sensory neurons.
2004,
Pubmed
,
Xenbase
Dyshlovoy,
Marine Compounds and Cancer: Where Do We Stand?
2015,
Pubmed
Frazão,
Sea anemone (Cnidaria, Anthozoa, Actiniaria) toxins: an overview.
2012,
Pubmed
García-Ferreiro,
Mechanism of block of hEag1 K+ channels by imipramine and astemizole.
2004,
Pubmed
Garg,
ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels.
2013,
Pubmed
,
Xenbase
Gómez-Lagunas,
Gating Modulation of the Tumor-Related Kv10.1 Channel by Mibefradil.
2017,
Pubmed
Gómez-Varela,
Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity.
2007,
Pubmed
Goujon,
A new bioinformatics analysis tools framework at EMBL-EBI.
2010,
Pubmed
Hartung,
Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody.
2011,
Pubmed
Hemmerlein,
Overexpression of Eag1 potassium channels in clinical tumours.
2006,
Pubmed
Jensen,
Understanding the molecular basis of toxin promiscuity: the analgesic sea anemone peptide APETx2 interacts with acid-sensing ion channel 3 and hERG channels via overlapping pharmacophores.
2014,
Pubmed
King,
A rational nomenclature for naming peptide toxins from spiders and other venomous animals.
2008,
Pubmed
Kiuru,
Exploring marine resources for bioactive compounds.
2014,
Pubmed
Kourie,
Properties of cytotoxic peptide-formed ion channels.
2000,
Pubmed
,
Xenbase
Lewis,
Therapeutic potential of venom peptides.
2003,
Pubmed
Martin,
Eag1 potassium channel immunohistochemistry in the CNS of adult rat and selected regions of human brain.
2008,
Pubmed
Mello de Queiroz,
Ether à go-go potassium channel expression in soft tissue sarcoma patients.
2006,
Pubmed
Moreels,
Expanding the pharmacological profile of κ-hefutoxin 1 and analogues: A focus on the inhibitory effect on the oncogenic channel Kv10.1.
2017,
Pubmed
,
Xenbase
Oliveira,
Development of a rational nomenclature for naming peptide and protein toxins from sea anemones.
2012,
Pubmed
Pardo,
Eag1 as a cancer target.
2008,
Pubmed
Pardo,
Oncogenic potential of EAG K(+) channels.
1999,
Pubmed
Pardo,
Approaches targeting K(V)10.1 open a novel window for cancer diagnosis and therapy.
2012,
Pubmed
Peigneur,
A natural point mutation changes both target selectivity and mechanism of action of sea anemone toxins.
2012,
Pubmed
,
Xenbase
Pennington,
Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.
2015,
Pubmed
Pettersen,
UCSF Chimera--a visualization system for exploratory research and analysis.
2004,
Pubmed
Rocha,
Cnidarians as a source of new marine bioactive compounds--an overview of the last decade and future steps for bioprospecting.
2011,
Pubmed
Saganich,
Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain.
2001,
Pubmed
Sanguinetti,
hERG potassium channels and cardiac arrhythmia.
2006,
Pubmed
Schumacher,
Gold from the sea: marine compounds as inhibitors of the hallmarks of cancer.
2011,
Pubmed
Shao,
Expression and significance of HERG protein in gastric cancer.
2008,
Pubmed
Srinivasan,
kappa-Hefutoxin1, a novel toxin from the scorpion Heterometrus fulvipes with unique structure and function. Importance of the functional diad in potassium channel selectivity.
2002,
Pubmed
Suarez-Jimenez,
Bioactive peptides and depsipeptides with anticancer potential: sources from marine animals.
2012,
Pubmed
Swartz,
Mapping the receptor site for hanatoxin, a gating modifier of voltage-dependent K+ channels.
1997,
Pubmed
Takahashi,
Solution structure of hanatoxin1, a gating modifier of voltage-dependent K(+) channels: common surface features of gating modifier toxins.
2000,
Pubmed
,
Xenbase
Torre,
Global cancer statistics, 2012.
2015,
Pubmed
Urrego,
Periodic expression of Kv10.1 driven by pRb/E2F1 contributes to G2/M progression of cancer and non-transformed cells.
2016,
Pubmed
Wang,
Molecular surface of tarantula toxins interacting with voltage sensors in K(v) channels.
2004,
Pubmed
,
Xenbase
Wang,
Saxitoxin is a gating modifier of HERG K+ channels.
2003,
Pubmed
Webb,
Comparative Protein Structure Modeling Using MODELLER.
2016,
Pubmed
Weber,
Silencing the activity and proliferative properties of the human EagI Potassium Channel by RNA Interference.
2006,
Pubmed
Wulff,
Voltage-gated potassium channels as therapeutic targets.
2009,
Pubmed
Zhang,
APETx1 from sea anemone Anthopleura elegantissima is a gating modifier peptide toxin of the human ether-a-go-go- related potassium channel.
2007,
Pubmed
Zheng,
Antitumor peptides from marine organisms.
2011,
Pubmed